Medicare covers GLP-1 drugs when they're prescribed for an approved medical condition like type 2 diabetes — but a long-standing law bars regular Part D from covering them for weight loss alone. That's the gap a new program fills: the Medicare GLP-1 Bridge, running July 1, 2026 through December 31, 2027, lets eligible Part D members get Wegovy, Zepbound or Foundayo for weight loss at a flat $50 copay per 30-day supply, with prior authorization. The catch: that $50 sits outside normal Part D, so it doesn't count toward your deductible or out-of-pocket maximum.
Key takeaways
- Part D covers GLP-1s for diabetes and other approved uses, not for weight loss on its own.
- The new GLP-1 Bridge (Jul 1, 2026–Dec 31, 2027) offers weight-loss coverage at a flat $50/month.
- You must be in a Part D plan, meet obesity/BMI criteria, and get prior authorization.
- The $50 is separate from Part D — it doesn't count toward your deductible or out-of-pocket cap, and Extra Help doesn't apply.
Has Medicare ever covered GLP-1s?
Yes — just not for weight loss. Since Medicare Part D began, federal law has excluded drugs used for weight loss from coverage. But the same GLP-1 molecule can be covered when it's prescribed for a different, FDA-approved reason. So Part D plans routinely cover Ozempic and similar drugs for type 2 diabetes, and coverage can extend to other approved indications — for example, semaglutide (Wegovy) to reduce cardiovascular risk, or tirzepatide (Zepbound) for obstructive sleep apnea with obesity.
The practical result has been a frustrating split: someone with type 2 diabetes could get a GLP-1 through Medicare, while someone with obesity and no qualifying second condition could not — even for the exact same drug. The Bridge program is designed to close that gap, at least temporarily.
What is the Medicare GLP-1 Bridge program?
The GLP-1 Bridge is a federal demonstration run by the Centers for Medicare & Medicaid Services (CMS). For the first time, it lets eligible Medicare Part D members get GLP-1 drugs specifically for weight loss at a predictable price. Here's the shape of it:
| Feature | Details |
|---|---|
| Runs | July 1, 2026 – December 31, 2027 |
| Copay | $50 per 30-day supply (flat, regardless of Part D stage) |
| Covered for weight loss | Wegovy (all formulations), the Zepbound KwikPen, and Foundayo |
| Who runs it | CMS, as a time-limited demonstration |
| Requires | Enrollment in a Part D plan + prior authorization |
| Counts toward deductible / out-of-pocket max? | No — it sits outside standard Part D |
The headline is that flat $50. For a class of drugs whose cash price often runs $1,000–$1,350 a month, that's a dramatic change for Medicare beneficiaries who previously had no weight-loss coverage at all.
Who qualifies, and how do you get it?
Eligibility runs through your prescriber and your plan, not a separate application:
- Be enrolled in a Medicare Part D plan. The Bridge operates alongside Part D, so you need that coverage in place.
- Meet the obesity/BMI criteria. Your provider must attest that you're being treated for obesity and that you meet the program's BMI and clinical criteria.
- Get prior authorization. Your prescriber submits a prior-authorization request before the medication is dispensed under the program.
What about the BALANCE Model?
You may also see news about the BALANCE Model, a broader CMS plan to test GLP-1 coverage across Medicare and Medicaid. In April 2026, CMS announced an indefinite delay of the Medicare Part D portion of the BALANCE Model, citing too little participation from Part D plan sponsors. The Medicaid component is moving ahead on its own timeline. To avoid a coverage gap in the meantime, the GLP-1 Bridge was extended through December 31, 2027. In short: the big permanent model is on hold, and the temporary Bridge is what's actually launching this summer.
What this means for you
If you're on Medicare and want a GLP-1 for weight loss, the Bridge is the route to watch from July 1, 2026 — talk to your prescriber about whether you meet the criteria and how prior authorization works for your plan. If you're seeking a GLP-1 for diabetes or another approved condition, your regular Part D plan may already cover it, so start there. Either way, confirm specifics with your plan and at Medicare.gov, because the rules around these programs are new and still evolving. Our cost & insurance guide and prescription guide walk through the rest of the access picture.
Frequently asked questions
Does Medicare cover Ozempic?
Yes — Part D plans generally cover Ozempic (semaglutide) when it's prescribed for type 2 diabetes, its approved use. Your exact copay depends on the plan's formulary, and prior authorization is common.
Does Medicare cover Wegovy or Zepbound for weight loss?
Not through standard Part D, which is barred by law from covering weight-loss-only drugs. But from July 1, 2026, the Medicare GLP-1 Bridge gives eligible Part D members Wegovy and Zepbound for weight loss at a $50 copay per 30-day supply, with prior authorization.
How much is the Medicare GLP-1 Bridge copay?
A flat $50 per 30-day supply, no matter which Part D stage you're in. It does not count toward your deductible or out-of-pocket maximum, and Extra Help / low-income subsidy doesn't apply to it.
When does the Medicare GLP-1 Bridge start and end?
It runs July 1, 2026 – December 31, 2027 (extended from an earlier end date after the broader Part D model was delayed).
Do I need prior authorization for the Bridge program?
Yes. Your prescriber submits a prior-authorization request attesting you're being treated for obesity and meet the program's BMI/clinical criteria. You must also be enrolled in a Part D plan.
Sources & further reading
- Centers for Medicare & Medicaid Services (CMS) — Medicare GLP-1 Bridge: cms.gov.
- KFF — What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge.
- Medicare.gov — Weight loss drugs coverage.
- Medicare Rights Center — "GLP-1 Weight-Loss Drug Demonstration Begins July 2026."